Optomed will supply diabetic retinopathy screening solution consisting of Optomed Aurora IQ fundus cameras and related software solutions to a public sector end customer in Valencia, Spain. The solution will be used to screen the local diabetic population for a potentially sight threatening disease, diabetic retinopathy. The total contract value is approximately EUR 800,000, and the delivery has a positive effect on the Devices segment's revenue for the second half of the year.

It does not have an effect on Optomed's financial outlook 2023.